BioSpace News Archive

Drug Development

Lemonex Announces IND Approval for Phase 1 Clinical Trial of LEM-S401, siRNA Gene Therapeutics With Nano-Drug Delivery Platform DegradaBALL®

Lemonex Inc. announced on the 19th of April that The Ministry of Food and Drug Safety has approved the Investigational New Drug for siRNA gene therapy LEM-S401 with their nano-drug delivery platform, DegradaBALL® on 15th of April.

April 26, 2022
·
3 min read
Business

TELA Bio to Announce First Quarter 2022 Financial Results

TELA Bio, Inc. announced that the company will report first quarter 2022 financial results on Tuesday, May 10, 2022.

April 26, 2022
·
2 min read
Business

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

BioXcel Therapeutics, Inc. announced that it will release its first quarter 2022 financial results on Monday, May 9, 2022 before the open of the U.S. financial markets.

April 26, 2022
·
4 min read
Lone Star Bio

Plus Therapeutics to Present at the 2022 Q2 Investor Summit

Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2022 Q2 Investor Summit on Tuesday, May 3, 2022, at 12:30 p.m. ET at the Westin New York Grand Central, New York, N.Y.

April 26, 2022
·
4 min read
Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

Algernon Pharmaceuticals Inc. is pleased to announce that its lead chronic kidney disease (“CKD”) drug NP-251 (“Repirinast”), reduced fibrosis by 56% with statistical significance, in a preclinical study investigating non-alcoholic steatohepatitis.

April 26, 2022
·
4 min read
Business

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

Marker Therapeutics, Inc. today announced it has entered into a services agreement with Wilson Wolf Manufacturing Corporation.

April 26, 2022
·
6 min read
Lone Star Bio

Nanoscope’s Vision Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as part of ARVO Annual Meeting in Denver May. 1-4, 2022

Nanoscope Therapeutics Inc. announced four presentations on the Company’s preclinical and clinical research in retinitis pigmentosa and Stargardt macular degeneration at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting, being held May 1 – 4, 2022, in Denver, Colorado.

April 26, 2022
·
2 min read
Business

Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer

Jnana Therapeutics today announced the appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer.

April 26, 2022
·
2 min read
Biotech Bay

Veeva Link Adds Four New Data Applications to Deliver Real-time Intelligence for Medical and Commercial Teams

Veeva Systems announced new Veeva Link data applications for medical, commercial, and key account management teams to gain real-time intelligence on health systems, scientific awareness and sentiment, and medical insights.

April 26, 2022
·
3 min read
Business

Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board

Ambagon Therapeutics today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board.

April 26, 2022
·
3 min read